Clinical Cancer Drugs - Volume 7, Issue 2, 2020

Although there are no 100% successful methods for treating cancer, chemotherapy is still one of the most commonly used approaches in its management. One of the most significant problems in cancer treatment is the resistance of cancer cells to chemotherapeutic agents. This review aims to unveil the factors contributing to this problem originally beginning with fundamental units like biomarkers and microRNAs. As mo Read More

Background: Regulation of protein phosphatase 2A (PP2A) plays an important role in hematologic and solid neoplasms. Therefore, the use of sphingosine analogs as anti-neoplastic drugs has shown potential due to their role as PP2A activators. Objective: Investigation of whether sphingosine analogs bind to endogenous inhibitor proteins of PP2A, such as I2 PP2A/SET and/or CIP2A, and whether this binding reactiva Read More

The COVID-19 pandemic has caused millions of infections and hundreds of thousands deaths in the world. The pandemic is still ongoing and no specific antivirals have been found to control COVID-19. The integration of Traditional Chinese Medicine with supportive measures of Modern Medicine has reportedly played an important role in the control of COVID-19 in China. This review summarizes the evidence of TCM in th Read More

In the last four decades, the emphasis was laid on the research of small organic molecules with potential anti-cancer activity. Linezolid was the first oxazolidinone derivative approved by FDA for MRSA treatment. Despite its major role in antimicrobial activity, these molecules display other properties, also serving as an antitumor agent. The importance of drug repurposing could be highlighted by the use of Oxazolidinone de Read More

Background: Statistical methods commonly used in survival analysis typically provide the probability that the difference between groups is due to chance, but do not offer a reliable estimate of the average survival time difference between groups (the difference between median survival time is usually reported). Objective: We suggest a Maximum-Entropy estimator for the average Survival Time Difference (MESTD) between grou Read More

Background: The goal of this study was to evaluate the anticancer and testosteroneinhibitory effects of 2‘-{[(E) androst-5-en-17-ylidene]methyl}-4‘,5‘-dihydro-1‘,3‘-oxazole-3β-oleate (Alsevirone-NF). Materials and Methods: PC-3, DU-145, LnCap and 22rv1 prostate cancer cell lines were used for MTT assay. 22rv1 subcutaneous cancer xenografts in Balb/c nude mice were used for in vivo efficacy experiments. T Read More

Background: The failure of imatinib therapy in patients with chronic myeloid leukemia (CML) is associated with the presence of leukemic stem cell (LSC), and the altered LSC level was reported to occur earlier in the progression of CML. Objective: The study aimed to assess the association between the level of LSC and treatment response among CML patients treated with imatinib mesylate. Methods: A cross-sectional study Read More

Background/Objective: With the increasing interest in natural products, a phase I openlabel study of OMN54 (Aneustat™) in patients with advanced malignancies was initiated to determine toxicity, maximum tolerated dose (MTD), dose limiting toxicities (DLT), and pharmacokinetics (PK). OMN54 is a multitargeted agent, combining three Chinese botanicals; Ganoderma lucidium, Salvia miltiorrhiza and Scutellaria barbata. Methods: Read More